Brentuximab vedotin has so far been approved for the treatment of CD30 + lymphoproliferative disorders such as classical Hodgkin lymphoma, systemic and primary cutaneous ALCL, MF, AITL and PTCL = NOS. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.